Identifying Recent HIV Infections Using the Avidity Index and an Automated Enzyme Immunoassay
Overview
Authors
Affiliations
We evaluated a procedure for identifying recent HIV infections, using sequential serum samples from 47 HIV-positive persons for whom the seroconversion date could be accurately estimated. Each serum sample was divided into two aliquots: one diluted with phosphate-buffered saline and the other diluted with 1 M guanidine. We assayed the aliquots with the automated AxSYM HIV1/2gO test (Abbott Diagnostics Division), without modifying the manufacturer's protocol. We then calculated the avidity index (AI): the ratio of the sample/cutoff value for the guanidine aliquot to that of the phosphate-buffered saline aliquot. We analyzed 216 serum samples: 34 samples were collected within 6 months of seroconversion (recent seroconversions), and 182 were collected after 6 months. The mean AIs, by time from seroconversion, were 0.68 +/- 0.16 (within 6 months) and 0.98 +/- 0.10 (after 6 months) (P < 0.0001). AI of <0.90 correctly identified 88.2% of recent infections but misclassified as recent infections 13.2% of serum samples collected afterward. The probability of an infection being classified as recent and having AI of > or = 0.90 would be 0.7% in a population with 5% recent infections. AI can identify with a certain degree of accuracy recent HIV infections, and being a quantitative index, it provides different levels of sensitivity and specificity, depending on the selected cutoff value. The standard assay procedure is not modified. This test is simple and inexpensive and could be used for surveillance, decision-making in treatment, and prevention.
HIV testing: the cornerstone of HIV prevention efforts in the USA.
Heffelfinger J, Owen S, Hendry R, Lansky A Future Virol. 2023; 6(11).
PMID: 37965646 PMC: 10644277. DOI: 10.2217/fvl.11.114.
Wulan W, Yunihastuti E, Arlinda D, Merati T, Wisaksana R, Lokida D iScience. 2023; 26(10):107986.
PMID: 37854696 PMC: 10579430. DOI: 10.1016/j.isci.2023.107986.
Yang H, Li Y, Xu M, Hu Y, Yuan F, Liu L Infect Drug Resist. 2023; 16:6535-6548.
PMID: 37814665 PMC: 10560476. DOI: 10.2147/IDR.S428744.
Slurink I, van de Baan F, van Sighem A, van Dam A, van de Laar T, de Bree G Front Reprod Health. 2022; 3:568611.
PMID: 36304001 PMC: 9580630. DOI: 10.3389/frph.2021.568611.
Mondi A, Pinnetti C, Lorenzini P, Plazzi M, Abbate I, Camici M Pharmaceuticals (Basel). 2022; 15(4).
PMID: 35455400 PMC: 9024471. DOI: 10.3390/ph15040403.